<DOC>
	<DOCNO>NCT01174238</DOCNO>
	<brief_summary>This two arm prospective Phase II pilot trial design determine optimal duration break axitinib chemotherapy carboplatin/paclitaxel melanoma . In study , 6 patient enrol Arm A , FLT PET scan ( 3'deoxy-3'-18F-Fluorothymidine positron emission tomography scan ) cohort . 30 patient enrolled Arm B , treatment-only cohort . 36 total patient enrol . The treatment schedule either cohort , exception FLT PET scan .</brief_summary>
	<brief_title>A Two Arm Trial Axitinib Carboplatin/Paclitaxel Melanoma ( CC # 10852 )</brief_title>
	<detailed_description>This two arm prospective Phase II pilot trial design determine optimal duration break axitinib chemotherapy carboplatin/paclitaxel melanoma . In study , 6 patient enrol Arm A , FLT-PET ( 3'deoxy-3'-18F-Fluorothymidine positron emission tomography scan ) cohort . 30 patient enrolled Arm B , treatment-only cohort . 36 total patient enrol . The treatment schedule dose either cohort , exception FLT PET scan . We enrol 6 patient Arm A , FLT-PET cohort , study financial consideration . Patients enrol Arm A first , FLT-PET cohort , accommodate radiological manufacture FLT-PET scan dye . It expensive manufacture usable forever . However patient unable participate Arm A logistical issue , i.e . able travel UCSF FLT-PET scan offer participation Arm B receive treatment available study . Each treatment cycle last 21days . During Cycle 1 , patient treat : Days 1-14 : axitinib 5 mg PO twice daily Days 15-21 : break treatment In cycle Cycle 1 , patient treat : Day 1 : paclitaxel 175 mg/m2 3 hour follow carboplatin AUC 5 ( AUC 5 term use describe dose carboplatin base patient 's height , weight kidney function ) 45 minute Days 1-14 : axitinib 5 mg PO twice daily Days 15-21 : break treatment Arm A : FLT PET cohort subject FLT PET scan 2 week prior day 1 day 14 , 17 , 21 cycle 1 . Arm B : Treatment-only patient receive administration axitinib carboplatin/paclitaxel schedule dose Arm A FLT PET scan . Patients Arm B standard tumor assessment FDG PET-CT scan ( F18-deoxyglucose positron emission tomography scan ) , CT Scans , MRI 's .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>1 . Histologically cytologically proven melanoma Stage IV unresectable stage III disease . 2 . Male female , age ≥ 18 year . 3 . Resolution acute toxic effect prior radiotherapy , chemotherapy surgical procedure NCI CTCAE Version 4.0 grade ≤1 . 4 . May ≤ 2 prior chemotherapy treatment prior immunotherapy treatment . These include dacarbazine and/or temozolomide carboplatin paclitaxel . 5 . At least 2 week since end prior systemic treatment ( 4 week bevacizumabcontaining regimen ) , radiotherapy , surgical procedure resolution treatmentrelated toxicity NCI CTCAE Version 4.0 grade ≤ 1 back baseline except alopecia hypothyroidism . 6 . No evidence preexist uncontrolled hypertension . The baseline systolic blood pressure reading must ≤140 mm Hg , baseline diastolic blood pressure reading must ≤90 mm Hg . Patients whose hypertension control antihypertensive therapy eligible . 7 . Adequate organ function define follow criterion : 1 . Serum aspartate transaminase ( AST ; serum glutamic oxaloacetic transaminase ( SGOT ) ) serum alanine transaminase ( ALT ; serum glutamic pyruvic transaminase ( SGPT ) ) ≤ 2.5 x local laboratory upper limit normal ( ULN ) , AST ALT ≤ 5 x ULN liver function abnormality due underlying malignancy 2 . Total serum bilirubin ≤ 1.5 x ULN ( Grade 01 ) 3 . Absolute neutrophil count ( ANC ) ≥ 1500 /ml 4 . Platelets ≥ 100,000/mL 5 . Hemoglobin ≥ 9.0 g/dL ( may transfuse erythropoietin treat ) 6 . Serum calcium ≥12.0 mg/dL 7 . Serum creatinine ≤ 1.5 x ULN 8 . Patients CNS ( central nervous system ) metastasis must either : 1 . Resected CNS metastasis without evidence recurrence &gt; 12 week , OR 2 . Brain metastasis treat stereotactic radiosurgery without evidence recurrence progression 12 week , OR 3 . Multiple brain lesion treat whole brain radiation therapy stable disease corticosteroid least 12 week prior start therapy , AND 4 . Without evidence leptomeningeal disease , AND 5 . Patients must neurologically intact . 9 . May previous adjuvant therapy interferon , vaccine , therapy IL2 GMCSF . 10 . Measurable disease RECIST criterion . 11 . ECOG performance status 0 1 . 1 . Major surgery within 4 week start study treatment . 2 . Radiation therapy within 2 week start study treatment . Prior palliative radiotherapy metastatic lesion ( ) permit , provide least one measurable lesion irradiate . 3 . NCI CTCAE version 4.0 grade 2 great hemorrhage within 4 week start study treatment . 4 . History hemoptysis bleed GI tract . 5 . History abdominal fistula perforation within 6 month prior start study treatment . 6 . History know carcinomatous meningitis , evidence symptomatic leptomeningeal disease screen CT MRI scan . 7 . Any follow within 6 month prior study drug administration : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack , pulmonary embolism . 8 . Hypertension control medication . 9 . Current use anticipate need treatment drug know potent CYP3A inhibitor ( grapefruit juice , verapamil , ketoconazole , miconazole , itraconazole , erythromycin , telithromycin , clarithromycin , indinavir , saquinavir , ritonavir , nelfinavir , lopinavir , atazanavir , amprenavir , fosamprenavir delavirdine ) . 10 . Current use anticipate need treatment drug know potent CYP3A CYP1A2 inducer ( ie , carbamazepine , dexamethasone , felbamate , omeprazole , phenobarbital , phenytoin , amobarbital , nevirapine , primidone , rifabutin , rifampin , St. John 's wort ) . 11 . Requirement anticoagulant therapy oral vitamin K antagonists . Lowdose anticoagulant maintenance patency central venous access devise prevention deep venous thrombosis allow . Therapeutic use low molecular weight heparin allow . 12 . Active seizure disorder evidence brain metastasis , spinal cord compression , carcinomatous meningitis . 13 . CNS disease stable dexamethasone 14 . Known human immunodeficiency virus ( HIV ) acquire immunodeficiency syndrome ( AIDS ) relate illness active infection 15 . Pregnancy breastfeed . Female subject must surgically sterile postmenopausal , must agree use effective contraception period therapy . All female subject reproductive potential must negative pregnancy test ( serum urine ) prior enrollment . Male subject must surgically sterile must agree use effective contraception period therapy . The definition effective contraception base judgment principal investigator designate associate . 16 . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration , may interfere interpretation study result , judgment investigator would make subject inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Axitinib</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paclitaxel</keyword>
</DOC>